RAPT Therapeutics Inc 2025年季度报告

orTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Emerging growth companyIf emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ TABLE OF CONTENTS Other Information Total operating expenses19,265(19,265)2,100 Unrealized loss on marketable securities(15)Total comprehensive loss$(17,180)$Net loss per share, basic and diluted$(0.08)$Weighted average number of shares used in computing net lossper share, basic and diluted215,410,25338,625,365 Proceeds from issuance of common stock under employee stock plans Net decrease in cash and cash equivalentsCash and cash equivalents at beginning of period Cash and cash equivalents at end of period 6See accompanying notes to condensed financial statements. NOTES TO CONDENSEDFINANCIAL STATEMENTS1. OrganizationDescription of the Business immunoglobulin E (“IgE”), a key driver of several allergic diseases. The Company’s oncology drug candidate, tivumecirnon, is anoral small-molecule C-C motif chemokine receptor 4 (“CCR4”) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors.In November 2024, the Company ceased development of zelnecirnon, its small molecule CCR4 antagonist for inflammatory disease. The Company is currently pursuing different novel CCR4 antagonists, whichthe Company believes may have improved safety margins. The Company is located in South San Francisco, California.Liquidity and Management PlansThe accompanying condensed financial statements have been prepared assuming that the Company will continue as a goingconcern. Since inception, the Company has incurred net losses and negative cash flows from operations. During the three monthsended March 31, 2025, the Company incurred a net loss of $17.2million and used $52.5million of cash in operations and capital equivalents and marketable securities will provide sufficient funds to enable it to meet its obligations for at least 12 months fromthe filing date of this Quarterly Report on Form 10-Q. The Company’s evaluation was based on the facts known as of the date of filing of this Quarterly Report on Form 10-Q.2. Summary of Significant Accounting Policies with the Securities and Exchange Commission (“SEC”). the information used by the CODM to allocate resources, the Company has determined it operates in one segment. 7 The CODM assesses performance for the Company’s operating segment and decides how to allocate resources based on theCompany’s cash runway and net loss that also is reported on the statements of operations and comprehensive loss as net loss. Netloss is used to monitor budget versus actual results. The measure of segment assets is reported on the balance sheets as total assets. As ofMarch 31, 2025 and December 31, 2024, all of the Company’s property and equipment was maintained in the United States. The Company determines employee, nonemployee and director stock-based compensation expense for all stock-based awardsbased on their grant date fair value using the Black-Scholes option-pricing model. For stock-based awards with service conditions only, stock-based compensation expense is recognized over the requisite service period using the straight-line method. Forfeituresare recognized as they occur.The fair value of restricted stock awards granted is determined based on the stock price on the date of grant. The estimatedfair value is amortized as compensation expense over the service period of the award. consideration of potential dilutive securities. Diluted net loss per common share is computed by dividing the net loss by the sum ofthe weighted average number of common shares and weighted average number of outstanding pre-funded warrants to purchase common stock plus the number of potential dilutive securities outstanding during the period calculated in accordance with thetreasury stock method. Diluted net loss per share is the same as basic net loss per share since the effect of potentially dilutivesecurities is anti-dilutive.The pre-funded common stock warrants are included in the calculation of basic and diluted net loss pershare as the exercise price of $0.001per share is non-substantive and the shares are issuable for little or no consideration. marketable securities with maturities beyond 12 months as current assets. The Company’s marketable securities are carried atestimated fair value, which is derived from independent pricing sources based on quoted prices in active markets for similarsecurities. Unrealized gains and losses are reported as a component of accumulated other comprehensive income (loss). The cost ofmarketable securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in otherincome, net on